Literature DB >> 18180350

Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans.

Letizia Angiolella1, Anna Rita Stringaro, Flavia De Bernardis, Brunella Posteraro, Mariantonietta Bonito, Laura Toccacieli, Antonella Torosantucci, Marisa Colone, Maurizio Sanguinetti, Antonio Cassone, Anna Teresa Palamara.   

Abstract

There is concern about the rise of antifungal drug resistance, but little is known about comparative biological properties and pathogenicity of drug-resistant strains. We generated fluconazole (FLC; CO23 RFLC)- or micafungin (FK; CO23 RFK)-resistant strains of Candida albicans by treating a FLC- and FK-susceptible strain of this fungus (CO23 S) with stepwise-increasing concentrations of either drug. Molecular analyses showed that CO23 RFLC had acquired markedly increased expression of the drug-resistance efflux pump encoded by the MDR1 gene, whereas CO23 RFK had a homozygous mutation in the FSK1 gene. These genetic modifications did not alter to any extent the growth capacity of the drug-resistant strains in vitro, either at 28 degrees C or at 37 degrees C, but markedly increased their experimental pathogenicity in a systemic mouse infection model, as assessed by the overall mortality and target organ invasion. Interestingly, no apparent increase in the vaginopathic potential of the strains was observed with an estrogen-dependent rat vaginal infection. The increased pathogenicity of drug-resistant strains for systemic infection was associated with a number of biochemical and physiological changes, including (i) marked cellular alterations associated with a different expression and content of major cell wall polysaccharides, (ii) more rapid and extensive hypha formation in both liquid and solid media, and (iii) increased adherence to plastic and a propensity for biofilm formation. Overall, our data demonstrate that experimentally induced resistance to antifungal drugs, irrespective of drug family, can substantially divert C. albicans biology, affecting in particular biological properties of potential relevance for deep-seated candidiasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180350      PMCID: PMC2258496          DOI: 10.1128/AAC.01223-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

2.  Bakers' yeast, a model for fungal biofilm formation.

Authors:  T B Reynolds; G R Fink
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

3.  Nonfilamentous C. albicans mutants are avirulent.

Authors:  H J Lo; J R Köhler; B DiDomenico; D Loebenberg; A Cacciapuoti; G R Fink
Journal:  Cell       Date:  1997-09-05       Impact factor: 41.582

4.  The enzymic degradation of an alkali-soluble glucan from the cell walls of Saccharomyces cerevisiae.

Authors:  G H Fleet; D J Manners
Journal:  J Gen Microbiol       Date:  1977-02

5.  Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic.

Authors:  L Angiolella; B Maras; A R Stringaro; G Arancia; F Mondello; A Girolamo; A T Palamara; A Cassone
Journal:  J Chemother       Date:  2005-08       Impact factor: 1.714

6.  Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Marilena La Sorda; Riccardo Torelli; Barbara Fiori; Rosaria Santangelo; Giovanni Delogu; Giovanni Fadda
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

7.  Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.

Authors:  M B Kurtz; G Abruzzo; A Flattery; K Bartizal; J A Marrinan; W Li; J Milligan; K Nollstadt; C M Douglas
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

8.  A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR.

Authors:  J Meijerink; C Mandigers; L van de Locht; E Tönnissen; F Goodsaid; J Raemaekers
Journal:  J Mol Diagn       Date:  2001-05       Impact factor: 5.568

Review 9.  Immunity to fungal infections.

Authors:  Luigina Romani
Journal:  Nat Rev Immunol       Date:  2004-01       Impact factor: 53.106

10.  Filamentous growth and elevated vaginopathic potential of a nongerminative variant of Candida albicans expressing low virulence in systemic infection.

Authors:  F De Bernardis; D Adriani; R Lorenzini; E Pontieri; G Carruba; A Cassone
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

View more
  19 in total

Review 1.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

2.  Deletion of ADA2 Increases Antifungal Drug Susceptibility and Virulence in Candida glabrata.

Authors:  Shang-Jie Yu; Ya-Lin Chang; Ying-Lien Chen
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.

Authors:  Sabrina Schubert; P David Rogers; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

4.  In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.

Authors:  Barbara Fiori; Brunella Posteraro; Riccardo Torelli; Mario Tumbarello; David S Perlin; Giovanni Fadda; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 5.  The development of fluconazole resistance in Candida albicans - an example of microevolution of a fungal pathogen.

Authors:  Joachim Morschhäuser
Journal:  J Microbiol       Date:  2016-02-27       Impact factor: 3.422

6.  In Vivo Paracoccidioides sp. Biofilm on Vascular Prosthesis.

Authors:  Maria Emilia Cattana; Maria Fernanda Tracogna; Isabel Marques; Florencia Rojas; Mariana Fernández; María de Los Ángeles Sosa; Javier Mussin; Gustavo Giusiano
Journal:  Mycopathologia       Date:  2017-03-23       Impact factor: 2.574

7.  Quercetin sensitizes fluconazole-resistant candida albicans to induce apoptotic cell death by modulating quorum sensing.

Authors:  B N Singh; D K Upreti; B R Singh; G Pandey; S Verma; S Roy; A H Naqvi; A K S Rawat
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

8.  Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.

Authors:  Brunella Posteraro; Rosa Martucci; Marilena La Sorda; Barbara Fiori; Dominique Sanglard; Elena De Carolis; Ada Rita Florio; Giovanni Fadda; Maurizio Sanguinetti
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

9.  Fluconazole assists berberine to kill fluconazole-resistant Candida albicans.

Authors:  De-Dong Li; Yi Xu; Da-Zhi Zhang; Hua Quan; Eleftherios Mylonakis; Dan-Dan Hu; Ming-Bang Li; Lan-Xue Zhao; Liang-Hua Zhu; Yan Wang; Yuan-Ying Jiang
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

10.  Pathways That Synthesize Phosphatidylethanolamine Impact Candida albicans Hyphal Length and Cell Wall Composition through Transcriptional and Posttranscriptional Mechanisms.

Authors:  Robert N Tams; Andrew S Wagner; Joseph W Jackson; Eric R Gann; Timothy E Sparer; Todd B Reynolds
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.